Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2010

View Archived Issues

Ensemble Discovery claims novel TNF-alpha inhibitors

Novel PBR ligands disclosed by University of Sydney

Novel tryptase beta inhibitors claimed by sanofi-aventis

Merck & Co. and Scynexis claim novel antifungal agents

Potential biomarkers for SR-13668 activity identified / News in Context

Hetero Research Foundation claims new sodium/glucose cotransporter 2 inhibitors

Clinical data reported on ER dipyridamole/aspirin in ischemic stroke/transient ischemic attack

Novel antibody-drug conjugate ASG-5ME shows preclinical potential for treatment of cancer

Results from ongoing phase I/II trial of HE-3235 in CRPC disclosed

Encouraging preliminary phase II data reported on Ad5-PSA vaccine in prostate cancer

FDA accepts for review NDA for fixed-dose Onglyza/metformin combination in type 2 diabetes

Acucela and Otsuka receive FDA fast track status for ACU-4429 in dry AMD

ALS Therapy Development Institute and Aestus to test potential ALS treatments

Zogenix begins pivotal phase III trial of ZX-002 for pain

Icagen reports phase IIa results on ICA-105665 in photosensitive epilepsy

Abraxis' Abraxane meets primary endpoint in phase III non-small cell lung cancer trial

Human Genome Sciences reports phase II data on mapatumumab in non-small cell lung cancer

Protalix initiates phase I trial of PRX-105 acetylcholinesterase for biodefense indications

Alkermes begins multidose phase I ALKS-37 trial in opioid-induced constipation

Cyplasin initiates hepatitis product development program

Nabi initiates second phase III trial of nicotine conjugate NicVAX vaccine

Novartis receives E.U. approval for meningococcal Menveo vaccine

Cangene receives European approval for ImmunoGam hepatitis B product

Antisoma commences phase IIb trial of AS-1411 in AML

Vectura and Sandoz revise VR-315 agreement for U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...